Home > Boards > US OTC > Cannabis > CV Sciences Inc. (CVSI)

FDA won’t be hurried to create CBD exceptions

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
playofthedivine Member Profile
 
Followed By 7
Posts 1,530
Boards Moderated 1
Alias Born 10/28/17
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/12/2019 4:06:28 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/8/2019 4:09:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/7/2019 4:04:05 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/6/2019 6:04:38 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 4:04:29 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/1/2019 6:39:46 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/31/2019 6:06:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/30/2019 4:02:27 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2019 4:20:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 6:01:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 4:08:24 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/27/2019 4:06:33 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:35:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 4:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2019 4:59:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 6:05:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2019 6:05:01 AM
PURA Gaps Open Over $0.08 Breaking 200 MA With Potential To Reach $0.25 To $0.35 As CBD Sector Heats Up InvestorsHub NewsWire - 6/11/2019 10:44:26 AM
Whether You Smoke It, Toke It or Drink It - These Stocks are Heating Up InvestorsHub NewsWire - 6/11/2019 8:05:00 AM
Bullish on (OTC:HIPH) as FDA Hearings Have CBD Coming to a Store Near You InvestorsHub NewsWire - 6/3/2019 12:15:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 4:20:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:10:29 PM
Hemp/CBD Companies Build New Distribution Channels and Drive Innovation Preparing for the Next Phase of Marketing InvestorsHub NewsWire - 5/8/2019 8:00:00 AM
CBD Gets Better and Bolder: Hemp CBD Companies Find New Distribution and Innovations InvestorsHub NewsWire - 5/3/2019 9:45:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/30/2019 4:40:09 PM
playofthedivine   Friday, 11/08/19 09:24:10 PM
Re: None
Post # of 61063 
FDA won’t be hurried to create CBD exceptions amid safety concerns, official says

Published 7 hours ago

Well, what can we say? Not a good sign, IMO.

A top official for the U.S. Food and Drug Administration (FDA) said the agency is concerned that developing a legal exception for supplements containing CBD could send the wrong message, both to companies interested in entering the market and consumers.

Lowell Schiller, the FDA’s principal associate commissioner for policy who is leading a panel investigating CBD as an ingredient in food, beverages and dietary supplements, told a group of nutritionists this week that the agency’s biggest concern is whether CBD is safe to consume in food and supplements, according to nutraceuticals industry trade publication Nutritional Outlook.

Speaking at a conference for the Council for Responsible Nutrition (CRN), Schiller conceded the FDA is getting pressure to move forward with a legal pathway for using CBD as an ingredient.
But he said the agency still does not have enough data to determine whether CBD is safe for long-term use, especially among vulnerable populations.

The CRN was one of several trade organizations that sent a joint letter to Congress in October, asking for legislation to establish CBD as a lawful dietary ingredient by waiving the federal Food, Drug and Cosmetic Act.

Schiller said CBD is not risk-free, pointing to concerns like potential liver toxicity and drug interactions, as well as animal studies indicating risk for the male reproductive system.

“We look at an FDA-regulated product containing CBD the same as we would look at an FDA-regulated product containing any other substances,” he said. “We apply the same tools and authorities and statutory provisions.

“At FDA, we don’t have one set of rules for cannabis-derived substances and another set of rules for other substances. We don’t approach CBD or other cannabis-derived substances with any sort of animus or imposing new burdens.”

Schiller said creating an exception for CBD without adequate safety data could:

Set a dangerous precedent for other unregulated substances in the future.
Encourage more bad actors to enter the market.
Impede the FDA’s ability to identify and address safety violations in the CBD market and send the incorrect message that FDA endorses CBD safety.
He said the agency plans to report on its progress soon. To read the full comments from Schiller’s address, click here. - https://www.nutritionaloutlook.com/regulatory/creating-legal-exception-cbd-supplements-short-full-safety-data-could-set-bad-precedent-says-fda-crn

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist